[SCHEDULE 13G/A] The Chemours Company SEC Filing
The Schedule 13G/A for The Chemours Company shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported aggregate beneficial ownership of 7,576,095 shares of Chemours common stock, equal to 5.1% of the class. The filing specifies shared voting power of 7,443,038 and shared dispositive power of 7,576,095, and reports sole voting and dispositive powers as 0.
The filing states the reporting persons "ceased to be beneficial owners of more than 5% of the outstanding Common Stock as of July 1, 2025." The amendment is signed August 7, 2025, and includes a Joint Filing Agreement as Exhibit I. No purchase prices, transaction dates, or intent to influence control are disclosed in the document.
La Schedule 13G/A per The Chemours Company indica che Millennium Management LLC, Millennium Group Management LLC e Israel A. Englander hanno dichiarato una detenzione di 7.576.095 azioni ordinarie di Chemours, pari al 5,1% della categoria. Il deposito specifica una potest脿 di voto condivisa di 7.443.038 e una potest脿 dispositiva condivisa di 7.576.095, e riporta poteri di voto e dispositivi esclusivi pari a 0.
Il documento afferma che i soggetti segnalanti "hanno cessato di essere beneficiari di oltre il 5% del capitale sociale in circolazione a partire dal 1掳 luglio 2025." L'emendamento 猫 firmato il 7 agosto 2025 e include un Accordo di Deposito Congiunto come Allegato I. Nel documento non sono indicati prezzi d'acquisto, date delle operazioni o intenzioni di influenzare il controllo.
El Schedule 13G/A de The Chemours Company muestra que Millennium Management LLC, Millennium Group Management LLC e Israel A. Englander comunicaron una posesi贸n total de 7.576.095 acciones ordinarias de Chemours, equivalente al 5,1% de la clase. La presentaci贸n especifica poder de voto compartido de 7.443.038 y poder dispositivo compartido de 7.576.095, e informa poderes de voto y dispositivos individuales como 0.
La presentaci贸n declara que las personas informantes "dejaron de ser beneficiarios de m谩s del 5% de las acciones en circulaci贸n a partir del 1 de julio de 2025." La enmienda est谩 firmada el 7 de agosto de 2025 e incluye un Acuerdo de Presentaci贸n Conjunta como Anexo I. No se revelan precios de compra, fechas de las transacciones ni intenci贸n de influir en el control en el documento.
The Chemours Company鞐� 雽�頃� Schedule 13G/A 靹滊鞐� 霐半ゴ氅� Millennium Management LLC, Millennium Group Management LLC 氚� Israel A. Englander電� Chemours 氤错喌欤� 7,576,095欤�毳� 齑� 氤挫湢頃橃棳 頃措嫻 瓿勱笁鞚� 5.1%毳� 氤挫湢頃� 瓴冹溂搿� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 瓿惦彊 鞚橁舶甓� 7,443,038欤�鞕赌 瓿惦彊 觳橂秳甓� 7,576,095欤�臧� 氇呾嫓霅橃柎 鞛堨溂氅�, 雼弲 鞚橁舶甓� 氚� 雼弲 觳橂秳甓岇潃 0搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
鞁犼碃靹滊姅 鞁犼碃鞚鸽摛鞚� "2025雲� 7鞗� 1鞚检潉 旮绊暣 氚滍枆欤检嫕鞚� 5% 齑堦臣 歆�攵勳潣 靾橃澋鞝� 靻岇湢鞛愱皜 鞎勲媹瓴� 霅橃棃雼�"瓿� 氇呾嫓頃╇媹雼�. 頃措嫻 靾橃爼靹滊姅 2025雲� 8鞗� 7鞚检棎 靹滊獏霅橃棃瓿�, 攵�靻嶌劀 I搿� 瓿惦彊 鞝滌稖 瓿勳暯鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 氍胳劀鞐愲姅 毵れ垬臧�, 瓯半灅鞚检瀽 霕愲姅 歆�氚瓣秾 頄夓偓 鞚橂弰鞐� 雽�頃� 鞝曤炒臧� 旮办灛霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Le Schedule 13G/A de The Chemours Company indique que Millennium Management LLC, Millennium Group Management LLC et Israel A. Englander ont d茅clar茅 une d茅tention globale de 7 576 095 actions ordinaires de Chemours, soit 5,1% de la cat茅gorie. Le d茅p么t pr茅cise un pouvoir de vote partag茅 de 7 443 038 et un pouvoir discr茅tionnaire partag茅 de 7 576 095, et signale des pouvoirs de vote et discr茅tionnaires exclusifs de 0.
Le d茅p么t indique que les personnes d茅clarantes 芦 ont cess茅 d'锚tre propri茅taires b茅n茅ficiaires de plus de 5 % du capital social en circulation 脿 compter du 1er juillet 2025. 禄 L'amendement est sign茅 le 7 ao没t 2025 et comprend un Accord de D茅p么t Conjoint en annexe I. Le document ne divulgue ni prix d'achat, ni dates de transaction, ni intention d'influencer le contr么le.
Das Schedule 13G/A f眉r The Chemours Company weist aus, dass Millennium Management LLC, Millennium Group Management LLC und Israel A. Englander insgesamt 7.576.095 Aktien der Stammaktien von Chemours gehalten haben, was 5,1% der Klasse entspricht. Die Einreichung spezifiziert ein gemeinsames Stimmrecht von 7.443.038 und ein gemeinsames Verf眉gungsrecht von 7.576.095, und gibt alleinige Stimm- und Verf眉gungsrechte mit 0 an.
In der Einreichung hei脽t es, die berichtenden Personen "h枚rten am 1. Juli 2025 auf, wirtschaftliche Eigent眉mer von mehr als 5% des ausstehenden Stammkapitals zu sein." Die 脛nderung ist vom 7. August 2025 unterzeichnet und enth盲lt eine gemeinsame Einreichungsvereinbarung als Anlage I. Im Dokument werden keine Kaufpreise, Transaktionsdaten oder eine Absicht zur Beeinflussung der Kontrolle offengelegt.
- Clear quantitative disclosure of aggregate shares (7,576,095) and percentage (5.1%)
- Amendment and signatures dated August 7, 2025, plus a Joint Filing Agreement (Exhibit I) enhance transparency
- Cessation of >5% ownership as of July 1, 2025, indicating the reporting persons no longer meet the >5% threshold
- No transaction details provided (no purchase/sale dates or prices disclosed in the filing)
Insights
TL;DR: Millennium entities reported a 5.1% position (7,576,095 shares) in Chemours, then ceased to own >5% as of July 1, 2025.
The Schedule 13G/A transparently discloses the aggregate share count and voting/dispositive breakdowns: 7,576,095 shares (5.1%) aggregate, shared voting power 7,443,038, and shared dispositive power 7,576,095. The document is an amendment filed and signed on August 7, 2025, and includes a Joint Filing Agreement. The filing does not include trade prices or specific transaction timing; it functions as regulatory disclosure of ownership levels.
TL;DR: Filing is routine disclosure of ownership limits and signatures; ceasing to exceed 5% changes reporting status under Schedule 13G.
The report indicates sole powers are 0 and that reported rights are shared through managed entities, consistent with holdings controlled by investment management structures. The explicit statement that the reporting persons ceased to be beneficial owners above the 5% threshold as of July 1, 2025 is the material governance detail; Exhibit I documents the parties' joint filing arrangement.
La Schedule 13G/A per The Chemours Company indica che Millennium Management LLC, Millennium Group Management LLC e Israel A. Englander hanno dichiarato una detenzione di 7.576.095 azioni ordinarie di Chemours, pari al 5,1% della categoria. Il deposito specifica una potest脿 di voto condivisa di 7.443.038 e una potest脿 dispositiva condivisa di 7.576.095, e riporta poteri di voto e dispositivi esclusivi pari a 0.
Il documento afferma che i soggetti segnalanti "hanno cessato di essere beneficiari di oltre il 5% del capitale sociale in circolazione a partire dal 1掳 luglio 2025." L'emendamento 猫 firmato il 7 agosto 2025 e include un Accordo di Deposito Congiunto come Allegato I. Nel documento non sono indicati prezzi d'acquisto, date delle operazioni o intenzioni di influenzare il controllo.
El Schedule 13G/A de The Chemours Company muestra que Millennium Management LLC, Millennium Group Management LLC e Israel A. Englander comunicaron una posesi贸n total de 7.576.095 acciones ordinarias de Chemours, equivalente al 5,1% de la clase. La presentaci贸n especifica poder de voto compartido de 7.443.038 y poder dispositivo compartido de 7.576.095, e informa poderes de voto y dispositivos individuales como 0.
La presentaci贸n declara que las personas informantes "dejaron de ser beneficiarios de m谩s del 5% de las acciones en circulaci贸n a partir del 1 de julio de 2025." La enmienda est谩 firmada el 7 de agosto de 2025 e incluye un Acuerdo de Presentaci贸n Conjunta como Anexo I. No se revelan precios de compra, fechas de las transacciones ni intenci贸n de influir en el control en el documento.
The Chemours Company鞐� 雽�頃� Schedule 13G/A 靹滊鞐� 霐半ゴ氅� Millennium Management LLC, Millennium Group Management LLC 氚� Israel A. Englander電� Chemours 氤错喌欤� 7,576,095欤�毳� 齑� 氤挫湢頃橃棳 頃措嫻 瓿勱笁鞚� 5.1%毳� 氤挫湢頃� 瓴冹溂搿� 氤搓碃頄堨姷雼堧嫟. 鞁犼碃靹滌棎電� 瓿惦彊 鞚橁舶甓� 7,443,038欤�鞕赌 瓿惦彊 觳橂秳甓� 7,576,095欤�臧� 氇呾嫓霅橃柎 鞛堨溂氅�, 雼弲 鞚橁舶甓� 氚� 雼弲 觳橂秳甓岇潃 0搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
鞁犼碃靹滊姅 鞁犼碃鞚鸽摛鞚� "2025雲� 7鞗� 1鞚检潉 旮绊暣 氚滍枆欤检嫕鞚� 5% 齑堦臣 歆�攵勳潣 靾橃澋鞝� 靻岇湢鞛愱皜 鞎勲媹瓴� 霅橃棃雼�"瓿� 氇呾嫓頃╇媹雼�. 頃措嫻 靾橃爼靹滊姅 2025雲� 8鞗� 7鞚检棎 靹滊獏霅橃棃瓿�, 攵�靻嶌劀 I搿� 瓿惦彊 鞝滌稖 瓿勳暯鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 氍胳劀鞐愲姅 毵れ垬臧�, 瓯半灅鞚检瀽 霕愲姅 歆�氚瓣秾 頄夓偓 鞚橂弰鞐� 雽�頃� 鞝曤炒臧� 旮办灛霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Le Schedule 13G/A de The Chemours Company indique que Millennium Management LLC, Millennium Group Management LLC et Israel A. Englander ont d茅clar茅 une d茅tention globale de 7 576 095 actions ordinaires de Chemours, soit 5,1% de la cat茅gorie. Le d茅p么t pr茅cise un pouvoir de vote partag茅 de 7 443 038 et un pouvoir discr茅tionnaire partag茅 de 7 576 095, et signale des pouvoirs de vote et discr茅tionnaires exclusifs de 0.
Le d茅p么t indique que les personnes d茅clarantes 芦 ont cess茅 d'锚tre propri茅taires b茅n茅ficiaires de plus de 5 % du capital social en circulation 脿 compter du 1er juillet 2025. 禄 L'amendement est sign茅 le 7 ao没t 2025 et comprend un Accord de D茅p么t Conjoint en annexe I. Le document ne divulgue ni prix d'achat, ni dates de transaction, ni intention d'influencer le contr么le.
Das Schedule 13G/A f眉r The Chemours Company weist aus, dass Millennium Management LLC, Millennium Group Management LLC und Israel A. Englander insgesamt 7.576.095 Aktien der Stammaktien von Chemours gehalten haben, was 5,1% der Klasse entspricht. Die Einreichung spezifiziert ein gemeinsames Stimmrecht von 7.443.038 und ein gemeinsames Verf眉gungsrecht von 7.576.095, und gibt alleinige Stimm- und Verf眉gungsrechte mit 0 an.
In der Einreichung hei脽t es, die berichtenden Personen "h枚rten am 1. Juli 2025 auf, wirtschaftliche Eigent眉mer von mehr als 5% des ausstehenden Stammkapitals zu sein." Die 脛nderung ist vom 7. August 2025 unterzeichnet und enth盲lt eine gemeinsame Einreichungsvereinbarung als Anlage I. Im Dokument werden keine Kaufpreise, Transaktionsdaten oder eine Absicht zur Beeinflussung der Kontrolle offengelegt.
FAQ
How many Chemours (CC) shares did Millennium report owning?
When did the reporting persons cease to be beneficial owners of more than 5% of CC?
What voting and dispositive powers were reported for CC?
Who filed the Schedule 13G/A for Chemours (CC)?
When was the amendment signed and who signed it?
